




















































A case report of an excellent response to
interferon- a in a patient with functional
metastasized neuroendocrine tumor refractory to
other treatments
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Abstract
Introduction: Interferon alpha (IFNa) has been used for a long time in patients with functionally active neuroendocrine tumors
(NET). However, due to the unfavorable toxicity profile of interferon, the perceived limited efficacy as well as the development of novel
substances, IFNa is only used sparingly in the treatment of NET to date.
Patients concerns and diagnosis:We describe the case of a 63-year-old male patient with highly differentiated, functional
NET of the ileum and synchronous liver metastasis.
Interventions: After failure of classical therapies including dose-intensified somatostatin analog treatment and palliative primary
tumor resection, a therapy with pegylated IFNa2a (135mg/wk) was initiated. Following this treatment, the patient fully recovered from
signs of hypersecretion and demonstrated an impressive tumor response.
Outcomes: Thirty months after initiating IFNa, the patient is still free of clinical symptoms and shows a sustained tumor response.
Notably, no relevant side effects were observed.
Conclusion: Our case report supports the use of IFNa in patients with functional NET refractory to classical treatments.
Abbreviations: 5-HIAA = 5-hydroxyindoleacetic acid, IFNa = interferon alpha, NEN = neuroendocrine neoplasia, NET =
neuroendocrine tumor, PET/CT = positron emission tomography/computed tomography, SSA = somatostatin analog, SSR =
somatostatin receptor.
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1. Introduction
Neuroendocrine neoplasia (NEN) comprise tumors that are
derived from the diffuse endocrine system. NEN are very
heterogeneous in terms of clinical symptoms and patients’
prognosis. While patients with well differentiated tumors display
an extraordinary favorable prognosis, patients with undifferen-
tiated tumors face a prognosis that is comparable or even worse
to that of small cell lung carcinoma. In patients with non-
functional diseases, NEN are mostly asymptomatic, while
patients with hormonal hypersecretion might display a so called
carcinoid syndrome, which includes diarrhea, abdominal pain,
flushing, bronchospasm and carcinoid heart disease.[1–3]
Surgical resection is the only curative treatment for neuroen-
docrine tumors (NET), although in over 50% of patients, NET
are metastasized at the time of diagnosis.[4] In non-resectable
cases, according to current guidelines, somatostatin analog
(SSAs) represent the first-line therapy for patients with functional
disease to achieve symptomatic relief and inhibit tumor
growth.[5] On a molecular level, the function of SSA can be
explained by binding of SSA to somatostatin receptors (SSR)
localized on the tumor cell surface. Currently available SSA
provide only moderate antiproliferative effects but effectively
inhibit hormonal secretion and ameliorate flushing and diarrhea
in about 75% of patients with carcinoid syndrome. Although
there are no randomized studies comparing different SSA, the
efficacy of available substances seems to be similar.[6] In the case
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of insufficiently controlled carcinoid syndrome, various thera-
peutic modalities including systemic and locoregional treatments
are available which, however, have not been compared with each
other, and whose efficacy can only be assessed empirically. In
many centers, high-dose SSA therapy is given in patients with
insufficient response to standard SSA.[7,8] Despite the toxicity of
this concept is low in most cases, prospective trials proving the
efficacy high-dose SSA in this indication are lacking. Besides
escalating the SSA dose, symptom control can also be achieved by
shortening the injection interval for example, 3 weeks.[9–11]
Moreover, the orally available serotonin synthesis inhibitor
telotristatetiprat (or telotristatethyl) can relieve diarrhea associ-
ated with carcinoid syndrome.[12]
Interferon alpha (IFNa) has been used for a long time in
patients with functionally active NETs. Administration of IFNa
is associated with an inhibition of hormone secretion and a
clinical improvement in up to 70% of NEN-patients.[13] Despite
large phase III- trials analyzing the efficacy of IFNa in NET are
lacking, several smaller studies have shown response rates in up
to 27% of patients and tumor stabilization rates of 40% upon
treatment with IFNa.[6] However, 2 randomized studies failed to
demonstrate a superiority of a combination of IFNa and SSA
compared to SSA alone.[14] Nevertheless, in comparison to SSA,
IFNa was associated with significantly higher rates of adverse
effects (loss of appetite, weight loss, fatigue, bone marrow
depression, hepatotoxic reaction, depressive syndrome, mental
changes, visual disturbances). Thus, based on its perceived
limited efficacy and an unfavorable toxicity profile, the use of
IFNa in patients with NET has considerably diminished in the
last years. We herein report the case of a patient with functional
ileal NET grade 2 (NET G2) and synchronous liver metastases,
who received IFNa therapy after intensified SSA monotherapy
and tumor debulking failed, resulting in a complete recovery from
symptoms of hormone hypersecretion and a sustained tumor
response of 30 months without any serious adverse events.
2. Case presentation
We report the case of a 63-year-old male patient who was
diagnosed in July 2016 with a highly differentiated functional
NET of the ileum and synchronous liver metastases. An overview
of the entire course of disease (including information on staging,
key diagnostics, therapies and response) is provided in Table 1.
When presenting at our outpatient unit, the patient was
suffering from hot flushes and diarrhea (up to 10x/day) since
several years. An ultrasonography performed by the family
practitioner of the patient had revealed several echogenic liver
lesions. We conducted a multi-slice computed tomography (CT)
revealing multiple liver lesions (initial hepatic tumor load 50%)
and a tumor formation of the ileum. A subsequently performed
DOTATOC- positron emission tomography/computed tomog-
raphy detected SSR positivity for the primary tumor but multiple
SSR negative liver metastases (Fig. 1). In further work-up, serum
Chromogranin A concentrations were significantly elevated
(29,924mg/L) and urinary 5-hydroxyindoleacetic acid (5-HIAA)
excretion was increased to 10,915mg/24h (Fig. 2). Immuno-
chemical analysis of a biopsy taken from a liver metastasis
revealed a strong expression of both synaptophysin and
chromogranin, ultimately proving the presence of a NET
differentiation. The proliferation rate according to antigen KI-
67 was 10% to 15%.
We initiated SSA therapy (octreotide depot 30mg LAR every
28 days) in August 2016. Follow up CT imaging in November
2016 revealed progressive disease showing a tumor progression
occurring in the liver (tumor load up to 60%). To prevent a
potentially life-threatening small bowel obstruction, the patient
was admitted to laparascopic right-sided hemicolectomy along
with right sided ureterolysis. Intraoperatively, peritoneal lesions
were detected that turned out as metastases of a neuroendocrine
tumor (antigen KI-67 17%), confirming peritoneal carcinomato-
sis. In this clinical constellation (progression and unresolved
flushing under standard dose SSA), we decided to administer SSA
Table 1
Course of disease.
Year Date Therapy Staging
2016 07/2016 Functional ileal NET G2 with hepatic metastases (hepatic tumor load
50%). Biopsy of hepatic metastases showed Ki 67 up to 15%
08/2016 Somatostatin analog (SSA) therapy (octreotid LAR 30 mg) every 28 d
11/2016 Hepatic progressive disease Hepatic tumor load up to 60%.
Peritoneal carcinomatosis.
11/2016 11/2016 laparascopic right-sided hemicolectomy, ureterolysis. Histology revealed Ki 67 up to 17%.
pT4 pN1(1/12) G2 R0 L0 V0
12/2016 SSA in a shortened schedule (octreotide depot 30mg LAR every 21 d)
2017 02/2017 Exclusion of Hedinger syndrome
05/2017 Add-on therapy with peg- IFNa 2a (135mg/wk) Progressive disease. Hepatic tumor load up to 70%.
11/2017 Hepatic partial remission.
Peritoneal carcinomatosis stable.
2018 02/2018 Hepatic partial remission.
Peritoneal carcinomatosis stable.
04/2018 Hepatic partial remission.
Peritoneal carcinomatosis stable.
09/2018 Hepatic partial remission. Hepatic tumor load 40%.
Peritoneal carcinomatosis stable.
2019 03/2019 Hepatic partial remission. Hepatic tumor load 30%.
Peritoneal carcinomatosis stable.
09/2019 Hepatic partial remission.
Peritoneal carcinomatosis stable.
SSA = somatostatin analog.
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therapy in a shortened schedule (octreotide depot 30mg LAR
every 21 days) trying to increase its efficacy. Nevertheless, the
patients’ general condition deteriorated, and the patient was
suffering from flush symptoms, diarrhea (up to 6x/d) as well as
significant weight loss (-3kg body weight within 4 months). CT-
imaging 4 months later revealed further hepatic tumor progres-
sion (Fig. 3) along with an elevation in chromogranin A and 5-
HIAA concentrations (Fig. 2).
IFNa has been associated to anti-secretory effects in patients
with NET, relieving clinical symptoms of carcinoid syndrome.
Moreover, it exerts antiproliferative effects in NET providing
tumor control in many patients .[13–15] We therefore decided to
initiate an add-on therapy with IFN taking into consideration
that alternative therapy options such as Peptide receptor
radionuclide therapy[16,17] or everolimus[16] were not considered
eligible due to negative SSR expression in liver metastases or, in
case of everolimus, the lack of anti-secretory effect and minimal
cytoreductive ‘potential. Locoablative procedures (Transcatheter
arterial chemoembolization, Afterloading, Selective internal
radiation therapy) could not be performed based on the high
hepatic tumor burden. Due to its better tolerability in comparison
to “conventional” IFN, pegylated IFNa2a was administered
(135mg/wk), although it is not specifically approved for NET
yet.[18]
Following this treatment, the patient fully recovered from signs
of hypersecretion and demonstrated an impressive tumor
response in CT imaging 4 months later (Fig. 3). Chromogranin
A and 5-HIAA concentrations immediately decreased after
initiation of therapy as demonstrated in Figure 2. Moreover, the
treatment was well tolerated, and the positive effect was not
associated with any adverse events. Subsequent staging exami-
nations until December 2019 showed a sustained partial
remission and stable peritoneal carcinomatosis. Thus, 30 months
after initiation of IFNa-treatment, the patient is in excellent
conditions with sustained tumor response and free from any
symptoms related to hormone hypersecretion.
3. Discussion and conclusion
We report the case of a 63-year-old male patient who was
diagnosed in July 2016 with a functional NET of the ileum and
synchronous liver metastases. After failure of standard treatment,
IFNa therapy was initiated and led to a dramatic clinical response
in terms of disappearance of all signs of hormone hypersecretion
as well as a sustained tumor shrinkage.
Hypersecretion of neuropeptides is a frequent clinical problem
in patients with NET.[19] The so called carcinoid syndrome (CS),
mainly consisting of diarrhea, cutaneous flush and respiratory
problems was first described in 1954 and later on associated with
tumoral secretion of serotonin and histamine.[20] Since CS occurs
almost exclusively when liver metastases are present, the
treatment-options are palliative in the most cases. According
to current guidelines, SSA, interferon-alpha, chemotherapy, loco-
regional therapies, target-therapies and peptide recep- tor
radionuclide therapy should be considered for treatment of
CS.[21] Data from recently published analyses revealed that both
lanreotide and octreotide improves diarrhea and flushing in
approximately 70% of patients. Notably, lanreotide showed very
similar effects as octreotide.[22,23] In patients refractory to a
standard SSA first-line treatment, dose escalation or decreasing
the injection interval has demonstrated efficacy in many patients
and represent the current standard treatment for those
patients.[5,8,11,24] Other options for systemic treatment are the
use of high-dose SSA[7,8] or of telotristat ethyl, an inhibitor of
Figure 1. Initial DOTATOC-PET/CT imaging of a functional ileal NET G2 with
synchronous hepatic metastases reveals: A) Somatostatin-Receptor (SSR)
positive ileal primary tumor and B) several SSR negative hepatic metastases
(initial hepatic tumor load 50%). PET/CT = positron emission tomography/
computed tomography. SSR = somatostatin receptor.
Figure 2. Chromogranin A concentration in serum and urinary 5-hydro-
xyindoleacetic acid concentration during the course of treatment. The graph
illustrates a drastic reduction of chromogranin A in serum and urinary 5-
hydroxyindoleacetic acid concentrations after initiation of therapy with IFNa2a
while only a slightly decrease was demonstrated during therapy with SSA
monotherapy and SSA therapy in a shortened interval (octreotide depot 30mg
LAR every 21 d). LAR = long-acting release, SSA = somatostatin analog.
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tryptophan hydroxylase.[25,26] Furthermore, locoregional thera-
pies including palliative surgery, radiofrequency ablation, trans-
arterial embolization and even selective internal radiation
therapy have been shown to improve CS.[5] As our patient
suffered from progressive hepatic disease and clinical deteriora-
tion under intensified SSA therapy and subsequent to palliative
resection of the ileal primary tumor, we initiated therapy with
IFNa2a.
IFNa has been recommended by many experts and current
European guidelines for well differentiated NET as monotherapy
or combination therapy with SSA in both antisecretory and
antiproliferative intention. Nevertheless, data supporting this
recommendation are scarce, the greatest experience is derived
from patients with metastatic intestinal NET, with many studies
including mixed cohorts of patients with gastroenteropancreatic
tumors. In 2 out of 3 randomized trials comparing SSA
monotherapy and combination treatment with SSA+ IFN-a,
no benefit of the combination therapy could be demonstrat-
ed,[14,27] the third study in patients with carcinoid syndrome
showed a better tumor control rate in the combination therapy
arm, but no significantly better 5-year survival.[28] In a recently
published retrospective study, IFN was associated with 15%
tumor responses with more than 50% reduction of tumor size,
further 39% stable diseases.[29] In our case, thirty months after
initiation of IFN treatment our patient still shows complete
recovery from clinical symptoms and a sustained biochemical and
tumor response going along with a significant reduction in tumor
size.
IFNa is associated with considerable toxicity including flu-like
symptoms, hematological toxicity, elevated transaminases,
Figure 3. Hepatic metastases in abdominal CT - imaging before (05/2017) and during (09/2018, 03/2019) treatment with IFNa2a. CT imaging before initiation
of treatment (05/2017) depicts a hepatic tumor load of 70%, whereas CT imaging in march 2019 shows a significant reduction of hepatic tumor load to 30%
(03/2019). CT = computed tomography.
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nausea, fatigue, and psychiatric sequelae that may significantly
limit life quality and may require discontinuation of treatment.
Our patient didn’t suffer from any adverse events during the
course of treatment. Nevertheless, since the benefit is not proven
in large randomized trials and the side-effect profile of other
treatments is more favorable than that of IFNa, IFNa should be
used only if other treatment options are not available, e.g. in later
lines of intestinal NET. In this context, it is important to note that
while European guideline recommend use of IFNa in NET as
second-line treatment,[16] other international guidelines such as
those from North American NET Society (NANETS) do not see
an indication for IFNa in these patients due to lack of evidence
supporting its use as well as its serious toxic profile.[14,17] In
contrast to European guidelines, NANETS guidelines recom-
mend 177Lu-dotatate as convenient regimen for second line
treatment ,[17] which was not applicable to our case, as hepatic
metastases were negative for SSR.
The exact mechanism driving the antiproliferative effects of
IFNa in NET are not clearly understood. Based on data from
other tumor entities, it seems likely that the intracellular IFN1
signaling affects cell differentiation, proliferation, and apoptosis.
Moreover, recent studies have revealed specific IFN1-regulated
genes that may contribute to IFN1-mediated suppression of
cancer progression and metastasis.[30] Moreover, it has recently
be demonstrated that IFNa activates the cellular autophagy
machinery in cell lines and that pharmacological inhibition of
autophagy dependent IFNa-induced apoptosis by activation of
the CASP8-BID pathway.[30] Finally, modification of the tumor
immunology might play a role in mediating effects of IFNa in
general as well as in our patient. Considering the dramatic and
long-lasting tumor control, it seems plausible that a previously
immunologically “cold” tumor was turned “hot” by IFNa and
was further controlled by the patients’ immune system. Similar
concepts were recently suggested for other substances activating
the immune system such as check-point-inhibitors.[31]
In summary, this case report supports the use of IFNa in
selected patients with functional NET refractory to classical
treatments.
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